Study of HP-002 for relapsed or refractory B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing an investigational drug called HP-002 for people with certain types of B-cell lymphoma that have come back or not responded to prior treatment. The study aims to see if HP-002 is safe and effective, offering a new option for patients who have limited choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell lymphoma (such as CLL/SLL, MCL, MZL, DLBCL, FL, WM, or PCNSL) that has returned or not responded to treatment.
- You should be able to care for yourself (ECOG performance status of 0-2).
- You must not have previously taken a BTK protein degrader.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This trial tests a new treatment called GI001 for people with B-cell lymphoma or B-cell leukemia that has come back or hasn't responded to previous treatments. It aims to see if GI001 can help when other options have failed, and it may be an option if you haven't had CAR-T therapy before.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new cell therapy called GI001 for patients with certain types of B-cell lymphoma or leukemia that have returned or not responded to previous treatments. It aims to see if this therapy can help control the disease.
This study tests an investigational treatment called B019 for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. It aims to see if this treatment can help when other treatments haven't worked.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.